Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monte Rosa Therapeutics

5.01
+0.39008.44%
Post-market: 5.040.0300+0.60%18:08 EDT
Volume:454.44K
Turnover:2.22M
Market Cap:308.16M
PE:64.66
High:5.04
Open:4.73
Low:4.61
Close:4.62
Loading ...

Monte Rosa Therapeutics Inc - Files for Mixed Shelf Offering of $400 Mln

THOMSON REUTERS
·
20 Mar

Monte Rosa Therapeutics Reports Q4 2024 Financial Results

TIPRANKS
·
20 Mar

BRIEF-Monte Rosa Therapeutics Q4 Operating Expenses USD 47.643 Million

Reuters
·
20 Mar

Monte Rosa Therapeutics Q4 Net Income USD 13.437 Million

THOMSON REUTERS
·
20 Mar

Monte Rosa Therapeutics Inc - Strong Cash Position Expected to Fund Operations Into 2028

THOMSON REUTERS
·
20 Mar

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results From Mrt-6160 and Mrt-2359 Programs

THOMSON REUTERS
·
20 Mar

Press Release: Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Dow Jones
·
20 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

GlobeNewswire
·
11 Mar

3 Top Cancer Biotechs to Keep An Eye On in 2025

Zacks
·
07 Mar

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
24 Feb

Conviction stock-picking drives biotech success: a biotech market review of 2024

LiveWire
·
17 Jan

Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength

TIPRANKS
·
10 Jan

Monte Rosa Therapeutics provide corporate update, key milestones 2025

TIPRANKS
·
10 Jan

Monte Rosa Therapeutics Inc: Biomarker and Activity Data, From Mrt-2359 Phase 1/2 Study Expected in Q1 2025

THOMSON REUTERS
·
10 Jan

Monte Rosa Therapeutics: Mrt-8102, a Nek7-Directed Mgd Targeting Diseases Driven by Il-1Β & Nlrp3 Inflammasome, on Track for Ind Filing in H1 2025

THOMSON REUTERS
·
10 Jan

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

THOMSON REUTERS
·
10 Jan

Monte Rosa Therapeutics: Year-End Cash & Equivalents Expected to Be $377 Mln as of Dec 31, 2024 and Anticipated to Fund Ops Into 2028

THOMSON REUTERS
·
10 Jan

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

GlobeNewswire
·
10 Jan

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
06 Jan